Engineering Nature's Defenses
Protecting Serious Wounds in an Age of Antibiotic Resistance
The world's antibiotics are becoming less effective. Gavia BIO is pioneering antimicrobial peptide therapeutics to protect wound care patients from life-threatening infections while addressing one of healthcare's most urgent challenges: antimicrobial resistance.
Our Approach
A Different Approach to Infection Prevention
Patients with intense wounds like serious burns are dangerously susceptible to infection, yet conventional antibiotics face growing resistance from evolving bacteria. Clinicians need new solutions that can protect healing without contributing to the cycle of antimicrobial resistance.
By learning from nature and combining broad-spectrum antimicrobial activity with a novel D-peptide structure, Gavia is pursuing a new class of topical therapeutics to help overcome the limitations of conventional antibiotics.
Lead Candidate
What If Antibiotics Could Resist Resistance?
Meet Minneganan.
Gavia BIO's Minneganan™ (compound name: DGL13K) is a nature-inspired, lab optimized antimicrobial peptide designed to support healing, provide broad-spectrum antimicrobial activity and help overcome conventional mechanisms of antibiotic resistance for patients experiencing some of the most difficult moments of human healing and recovery.
Supported by years of University of Minnesota research, patented intellectual property, peer-reviewed publications and methodical preclinical development, Minneganan is initially being developed as a topical formulation or hydrogel for hospital burn units and trauma centers.
Demonstrated antimicrobial activity across 26 tested bacterial species
Effective against clinically important resistant pathogens
Nature-inspired, engineered peptide platform
Antimicrobial Peptides
Protecting One of Medicine's Greatest Discoveries
Since the 1940s
Antibiotics transformed modern medicine–making once-deadly infections treatable and enabling increasingly sophisticated care.
Today
Bacteria continues to evolve resistance, steadily eroding the effectiveness of these essential medicines and creating a need for new approaches.
Gavia BIO
We’re engineering antimicrobial peptides designed to overcome conventional resistance mechanisms– beginning with better protection for burn patients.
Our Vision
Develop antimicrobial therapies that remain effective longer, improve patient outcomes and help preserve one of medicine’s most valuable resources.